News
Reports Q1 reveue $6.7B, consensus $6.81B. “Gilead (GILD) had a strong start to the year driven by excellent commercial and clinical execution ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback